Antibody compounds with reactive arginine and related antibody drug conjugates
AssigneeUniversity of Florida Research Foundation, Inc.
InventorsChristoph Rader, Dobeen Hwang, Napon Nilchan
Life of this patent
Estimating the term…
Abstract
The present invention provides antibody compounds that contain a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft (38C2_Arg). The invention also provides antibody drug conjugate compounds (ADCs) that contain cargo moieties that are site-specifically conjugated to the engineered arginine residue in the 38C2_Arg variant antibody. Further provided in the invention are therapeutic applications of the compounds.
Claims34
An antibody compound, comprising a variant of catalytic antibody 38C2 (38C2_Arg), or antigen binding fragment thereof, that contains a substitution of arginine for the reactive lysine residue (Lys99) in the hydrophobic cleft.
An antibody drug conjugate (ADC) comprising at least one drug moiety that is conjugated to an antibody compound via a reactive arginine residue in the antibody compound, wherein the antibody compound comprises a variant of catalytic antibody 38C2 (38C2_Arg), or antigen binding fragment thereof, that contains a substitution of arginine for the reactive lysine residue in the hydrophobic cleft.
Dependencies are inferred from the claim text.